Join
Live feed
·
PRReleasevia Quantisnow
Exelixis Inc. logo

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

ByQuantisnow·Wall Street's wire, on your screen.
EXEL· Exelixis Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EXEL (Exelixis Inc.) and more on Quantisnow.